Semisynthetic Pneumococcal Glycoconjugate Nanovaccine.

Area of Science:

• Vaccinology
• Nanotechnology
• Immunology

Background:

• Pneumococcal conjugate vaccines provide good protection but can be improved.
• Novel delivery systems are needed to broaden protection and enhance immunogenicity in diverse populations.

Purpose of the Study:

• To develop and evaluate chitosan nanoparticles (CNPs) for delivering pneumococcal glycoconjugate (GC) antigens.
• To assess the safety, uptake, and immunogenicity of GC-loaded CNPs (GC-CNPs).

Main Methods:

• Encapsulation of a synthetic tetrasaccharide mimicking *Streptococcus pneumoniae* serotype 14 capsular polysaccharide (CP14) linked to Pneumococcal surface protein A (PsaA) into chitosan NPs.
• In vitro assessment of GC-CNP toxicity and uptake by human monocyte-derived dendritic cells (MoDCs).
• In vivo evaluation of the immune response in mice after subcutaneous administration of GC-CNPs versus naked GC.

Main Results:

• GC-CNPs demonstrated no toxicity to MoDCs and enhanced antigen uptake.
• GC-CNPs exhibited superior immunostimulatory properties compared to non-encapsulated GC.
• Subcutaneous administration of GC-CNPs in mice elicited a 100-fold higher IgG response than naked GC.

Conclusions:

• Chitosan-based nanoparticles are a promising platform for efficient delivery of pneumococcal glycoconjugate antigens.
• GC-CNPs enhance antigen immunogenicity and show potential for developing next-generation pneumococcal vaccines.
• This nanovaccine approach may extend protection to additional serotypes and improve efficacy in vulnerable groups.